Three distinct genes encode α 1 -adrenoceptors. Although homodimers of each subtype have been reported, certain but not all combinations of heterodimers of the α 1 -adrenoceptors appear to form. Key studies in this field are reviewed and the approaches that have been applied to monitoring the selectivity and the basis of α 1 -adrenoceptor dimerization are discussed.
Introduction
GPCRs (G-protein-coupled receptors) are encoded by one of the largest gene families in the human genome. In the region of 400 genes encode GPCRs that respond to endogenously produced ligands and some 350 others encode GPCRs that respond to exogenous ligands, including odorants and tastes. In the recent past, it has become increasingly clear that GPCRs can exist as dimers or higher-order oligomers and that this may be integral to their function [1] [2] [3] . The rhodopsin-like or class A GPCRs are by far the largest family with the metabotropic glutamate receptor-like, class C receptors being the smallest. Despite the small number of class C GPCRs, studies on their expression and function have been integral to appreciation of the importance of dimerization for function. For example, although cloning of a seven-transmembrane polypeptide, class C GPCR that bound a high-affinity GABA B (γ -aminobutyric acid B) receptor antagonist seemed initially to identify this receptor [4] , it was soon apparent that this polypeptide was not effectively transported to the surface of transfected cells. Furthermore, response of this receptor to GABA was either poor or non-existent. The recognition that co-expression of a second, highly homologous GPCR, the GABA B r2, was required to allow effective cell-surface delivery and function of the original polypeptide, now known as the GABA B r1, helped to define the functional GABA B receptor as an obligate heterodimer [5] [6] [7] . Although a special case, in that only the GABA B r1 is capable of binding GABA and hence initiating a signal, the requirement for the GABA B r2 to allow effective G-protein coupling [8] provided an intellectual framework for related studies on homodimers and heterodimers of other GPCRs. Equally, taste cells that express one or pair-wise combinations of three class C GPCRs, T1R1, T1R2 and T1R3, allow the detection of sugars and amino acids that are mainly associated with positive taste sensations. Sweet and umami (the taste of monosodium glutamate) are the main attractive taste modalities in man. Although there are means to detect sweet and umami tastes in the absence of T1R3 [9] , the heterodimer pairing of T1R1 + T1R3 generates an umami sensor, whereas the heterodimer T1R2 + T1R3 defines a sweet receptor [10, 11] . The requirement for co-expression of specific pairs of class C GPCRs to produce a particular pharmacology of response is entirely consistent with key physiological roles requiring heterodimer formation. Such observations have influenced the thinking about the contribution that heterodimerization between class A GPCRs might provide to complex pharmacologies [1] [2] [3] .
Quaternary structure and the function of class A GPCRs
Expression of a single DNA or cDNA encoding a class A GPCR sequence in a heterologous cell line results, in most cases, in the production of a receptor capable of re-capitulating the pharmacology of a well-known pattern of physiological responses. For example, after isolation of genomic DNA, known initially as G21 [12] , expression generated a ligand-binding site characteristic of the pharmacologically defined 5-HT 1A receptor [12] and responses to 5-HT and other relevant agonists that were blocked by antagonists with 5-HT 1A receptor pharmacology. Whereas it could be argued that the cells used for expression harboured other endogenously expressed polypeptides required to interact with the protein product of the G21 DNA to generate this receptor, the most obvious explanation was that the molecular structure of the 5-HT 1A receptor was encoded entirely by the G21 DNA [12] . Of course, such studies did not address whether the 5-HT 1A receptor functioned as a monomer. A wide range of approaches has been employed in recent years to indicate that class A GPCRs can exist as dimeric complexes. These include co-immunoprecipitation studies that employ differentially epitope-tagged forms of a single GPCR [13] [14] [15] , biophysical techniques utilizing a number of resonance energy transfer techniques [16] [17] [18] [19] [20] [21] [22] and functional reconstitution after co-expression of pairs of non-functional constructs harbouring distinct inactivating mutations [23] [24] [25] . All of these techniques have inherent limitations. For example, the resonance energy transfer approaches can only formally define that the appropriately labelled GPCRs are within proximity limits defined by the basis of the techniques, and the co-immunoprecipitation studies require membrane fragments to be fully solubilized to provide convincing evidence for direct protein-protein interactions. The use of combinations of distinct approaches that each intimate physical interactions increases confidence in such conclusions [26] . Most directly, the application of atomic force microscopy to rod outer segments has indicated the photon receptor rhodopsin to be organized in paracrystalline 'arrays of dimers' [27] . It is clearly possible that the high local concentration of rhodopsin in situ imposes physical and organizational constraints that may not be generally applicable. Despite this caveat, these studies remain the best example of the structural organization of a class A GPCR in its native environment.
α 1 -Adrenoceptors
GPCRs that respond to adrenaline and noradrenaline are classified as α 1 -, α 2 -or β-adrenoceptors [28] [29] [30] [31] [32] based on the relative potencies of the endogenous agonists as well as a series of synthetic ligands. In man, three distinct genes encode the α 1a -, α 1b -and α 1d -adrenoceptor subtypes. Subtype-selective pharmacology is relatively poor and adrenaline and noradrenaline display similar potencies at each subtype and between subtypes. Before the generation of mice in which one or more of these genes is inactivated it was particularly challenging to ascribe specific functions to a particular α 1 -adrenoceptor subtype, especially as the subtypes are frequently co-expressed. Despite each subtype being predominantly coupled with members of the G q /G 11 family of heterotrimeric G-proteins, they do display significant differences in the effectiveness of signal generation [32] .
Dimerization of α 1 -adrenoceptor subtypes

Homodimerization
As with many other GPCRs, initial indications of a quaternary structure for the α 1 -adrenoceptor subtypes was based on the observation of multiple immunoreactive bands subsequent to SDS/PAGE resolution of epitope-tagged forms of the α 1 -adrenoceptor subtypes [33] . Interestingly, in these studies, only bands corresponding to monomers were observed after photoaffinity labelling with the antagonist [ 125 I]arylazidoprazosin, leading to the suggestion, contrary to many current views on the relevance of GPCR dimerization [1] [2] [3] , that the monomeric form might equate with the active state. A range of different techniques has subsequently been employed. FRET (fluorescence resonance energy transfer) studies were employed to demonstrate homodimer or oligomer complexes for both the α 1a -and α 1b -adrenoceptor when these were expressed in HEK-293 cells (human embryonic kidney 293 cells) [34] and that addition of neither agonist nor antagonist/inverse agonist ligands altered these interactions. Similar conclusions were reached for the α 1b -adrenoceptor by examining the capacity of pairs of distinct, inactive α 1b -adrenoceptor-Gα 11 fusion proteins to reconstitute agonist-mediated function when they were co-expressed in either HEK-293 cells or in mouse embryo fibroblasts that lack expression of Ca 2+ -mobilizing G-proteins [25] . Similar studies with such fusions that incorporate the α 1a -adrenoceptor have produced similar results [26] . Recently, biomolecular fluorescence complementation studies have also been employed to support a dimeric structure of the α 1b -adrenoceptor when expressed in HEK-293 cells (J.F. López-Giménez, J. Pediani and G. Milligan, unpublished work).
At steady state, it is frequently observed that a significant fraction of α 1 -adrenoceptors is present inside cells [26, [35] [36] [37] . Using N-terminally epitope-tagged forms of the α 1b -adrenoceptor, time-resolved (Tr)-FRET performed on intact cells demonstrated that the cell-surface fraction of the α 1b -adrenoceptor in HEK-293 cells also contained dimers/ oligomers [25] . Equivalent observations have been made for the α 1a -adrenoceptor [26] . Extending this approach to membrane fractions of HEK-293 cells resolved by sucrose-density sedimentation demonstrated that the intracellular population of the α 1a -adrenoceptor also contained dimers/oligomers [26] , perhaps suggesting that this receptor is a constitutive dimer/oligomer at different stages in its life history.
C-terminal truncation mutants of α 1 -adrenoceptor subtypes are capable of interacting as effectively as the wild-type forms, indicating that the intracellular C-terminal tail of these receptors is not required for homodimeric-oligomeric interactions [34, 38] . Furthermore, a series of splice variants of the α 1a -adrenoceptor vary only in the C-terminal tail region and various combinations of these form dimericoligomeric complexes as effectively as the prototypic and best-studied form of the receptor [26, 39] . As noted earlier, the addition of agonist ligands does not appear to alter the dimeric/oligomeric status of α 1 -adrenoceptor subtypes. It is therefore interesting to note that a well-characterized mutant (Ala 293 → Glu) form of the α 1b -adrenoceptor that has increased agonist-independent or constitutive activity also forms a dimeric/oligomeric complex [34] . Although the extent to which this mutant mimics the agonist-occupied state has been questioned [40] , these results certainly do not provide support for a model in which α 1b -adrenoceptor activation would result in dissociation of the receptor dimer. Such a scenario has been suggested for certain other class A GPCRs [41, 42] .
The molecular basis of α 1 -adrenoceptor homodimerization remains to be fully elucidated. A sequence akin to the glycophorin-A dimerization interface is present in transmembrane region I of the α 1b -adrenoceptor. However, mutation of this region neither modifies FRET signals [34] nor prevents interactions between the full-length α 1b -adrenoceptor and a fragment of the receptor consisting of the N-terminal region and transmembrane helix I [25] . In contrast, an equivalent sequence in transmembrane region I of the yeast pheromone receptor does appear to play a key role in dimerization [43] . Using a 'one transmembrane helix at a time' chimaeric swap strategy with sequences from the related β 2 -adrenoceptor, some undefined feature of transmembrane helix I was shown to be important for α 1b -adrenoceptor homodimerization [34] and there were also effects produced after swapping of transmembrane helix VII [34] . On examining interactions between various fragments and the full-length α 1b -adrenoceptor, Carrillo et al. [43a] have suggested that this GPCR is probably organized further within an oligomeric complex because the range of interaction points appear too widespread to be consistent with a single-contact interface dimer. However, further work, perhaps akin to cysteine cross-linking studies on the complement C5a receptor [44] or the models derived from atomic force microscopy analysis of the in situ organization of rhodopsin [27] , will be required to validate this hypothesis.
Heterodimerization
As they are highly homologous within the transmembrane helices, it might be anticipated that the three α 1 -adrenoceptor subtypes could form heterodimers in cells in which they are co-expressed. This prediction seems, however, to be only partially correct. FRET studies have confirmed the ability of the α 1a -and α 1b -adrenoceptor subtypes to interact when expressed in HEK-293 cells [34] . However, although in co-immunoprecipitation studies interactions of the α 1b -adrenoceptor with both the α 1a -and α 1d -adrenoceptor subtypes could be shown, no interactions between co-expressed forms of the α 1a -and α 1d -subtypes were observed [38] . The molecular basis for this has not been explored. Correlated mutation analysis has been suggested to provide a means to identify amino acids in closely related sequences that have a tendency to stay the same or to be mutated together during evolution [45, 46] . Such analyses may provide a useful strategy to identify key dimerization interfaces for the pairs of α 1 -adrenoceptor subtypes that are able to interact.
Co-expression of α 1 -adrenoceptor subtypes [38] or C-terminal splice variants of the α 1a -adrenoceptor [26] does not have a significant effect on receptor pharmacology. However, co-expression of the α 1b -adrenoceptor with the α 1d -adrenoceptor has recently been reported to improve substantially cell-surface delivery of the α 1d -adrenoceptor [47] . This was not produced by co-expression of the α 1a -adrenoceptor with the α 1d -adrenoceptor [47] , consistent with the earlier report that these two subtypes do not interact [38] . The enhanced transport of the α 1d -adrenoceptor to the cell surface was also produced by a mutant of the α 1b -adrenoceptor that is unable to signal and this resulted in enhanced agonist-mediated signalling [47] , presumably through the α 1d -adrenoceptor. These observations may have physiological significance in situations in which co-expressed α 1 -adrenoceptor subtypes have kinetically different expression profile patterns. It has also been noted that, when expressed in DDT 1 -MF2 cells, the α 1d -adrenoceptor is effectively trafficked to the cell surface. Endogenous expression of the α 1b -adrenoceptor by these cells has been suggested to provide a molecular explanation [47] . An obvious expectation of this hypothesis is that selective small interfering RNA-induced knockdown of the α 1b -adrenoceptor in DDT 1 -MF2 cells would result in intracellular accumulation of endogenously introduced α 1d -adrenoceptors. It should also be expected that a much larger proportion of the α 1d -adrenoceptor should be intracellular in tissues of α 1b -adrenoceptor knockout mice that, in wild-type animals, are known to co-express these two receptor subtypes.
One concern with many GPCR co-immunoprecipitation experiments is that detergent-mediated dissolution of cellular membranes might result in artifactual aggregation [48] . A number of studies on heterodimerization involving α 1 -adrenoceptor subtypes have thus attempted to provide negative controls and/or to assess the relative propensity of different GPCRs to interact. Stanasila et al. [34] used FRET to demonstrate little propensity of the α 1b -adrenoceptor to interact with rather distantly related class A GPCRs, including the NK1 tachykinin and the CCR5 chemokine receptors. Equally, however, the closely related β 2 -adrenoceptor did not generate an obvious heterodimer with the α 1b -adrenoceptor [34] . In part, this provided the rationale in attempting to identify the regions of the α 1b -adrenoceptor responsible for homodimerization by replacing one transmembrane region at a time with the equivalent section of the β 2 -adrenoceptor [34] . Interactions between the histamine H 1 receptor and both the α 1a - [26] and α 1b -adrenoceptors [25] appear to be limited and by applying saturation bioluminescence resonance energy transfer, hetero-interactions between the α 1a -adrenoceptor and the DOP opioid receptor were shown to be some 75-fold lower in affinity than α 1a -adrenoceptor homo-interactions [26] . Such results suggest that even in cells in which these GPCRs are co-expressed the proportion of these GPCRs present in such heterodimers is probably vanishingly small.
Conclusions
The basis and relevance of GPCR dimerization is currently one of the most actively studied areas of GPCR structure and function. The α 1 -adrenoceptor family provides a very useful grouping in this regard. All three members are capable of forming homodimers but there is apparent selectivity in their capacity to heterodimerize. As evidence suggests that the interface(s) responsible for dimerization must reside within the transmembrane helices and because these regions are highly conserved between family members, the α 1 -adrenoceptors are well suited to both informatic and direct experimental analyses of the molecular basis of homo-and heterodimerization. Rapid progress in understanding is to be expected.
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